Visualitza per autor "Tan, Daniel S. W."
Ara mostrant els elements 1-3 d 3
-
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor
Harding, James J.; Tan, Daniel S. W.; Bedard, Philippe L.; Rodon Ahnert, Jordi; Doi, Toshihiko; Bauer, Todd (Springer, 2019-04-15) -
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
Tan, Daniel S. W.; Martin, Miguel; Ochoa de Olza Amat, Maria; Sarantopoulos, John; Carvajal, Richard; Schoffski, Patrick (BMJ, 2022-02) -
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
Griesinger, Frank; Thomas, M.; Baik, Christina; Tan, Daniel S. W.; Garralda Cabanas, Elena; Subbiah, Vivek; Curigliano, Giuseppe (Elsevier, 2022-11)